Quick Answer
Anika Therapeutics, Inc. reported Stockholders Equity of $143.47 million for fiscal year 2025.
Anika Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $143.47M | -6.8% |
| 2024 | $153.99M | -27.5% |
| 2023 | $212.26M | -25.7% |
| 2022 | $285.56M | -0.5% |
| 2021 | $287.08M | +5.4% |
| 2020 | $272.40M | -5.5% |
| 2019 | $288.38M | +9.4% |
| 2018 | $263.61M | +0.0% |
| 2017 | $263.49M | +18.3% |
| 2016 | $222.77M | +5.7% |
| 2015 | $210.85M | +18.4% |
| 2014 | $178.10M | +31.3% |
| 2013 | $135.63M | +24.5% |
| 2012 | $108.92M | +14.9% |
| 2011 | $94.76M | +11.2% |
| 2010 | $85.19M | +3.7% |
| 2009 | $82.14M | +35.2% |
| 2008 | $60.76M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $146.81M | -18.4% | -0.6% |
| June 30, 2025 | $147.67M | -29.8% | -0.5% |
| March 31, 2025 | $148.40M | -28.8% | -3.6% |
| December 31, 2024 | $153.99M | -27.5% | -14.4% |
| September 30, 2024 | $179.86M | -33.5% | -14.5% |
| June 30, 2024 | $210.34M | -23.2% | +0.9% |
| March 31, 2024 | $208.54M | -24.9% | -1.8% |
| December 31, 2023 | $212.26M | -25.7% | -21.5% |
- Anika Therapeutics, Inc. showed a decrease of -6.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, Anika Therapeutics, Inc.’s stockholders equity has grown by 136.1% (from $60.76 million to $143.47 million).
- The most recent figure is from Anika Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: